title: Targeting vascular endothelial growth factor receptor signaling in renal cancer: the sooner the better?
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Amanda
authors.initials: A
authors.lastname: Leiter
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: matthew.galsky@mssm.edu.
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Galsky
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D007191:Indazoles / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D010535:Laparoscopy; D008297:Male; D020360:Neoadjuvant Therapy; D009392:Nephrectomy; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D000077784:Axitinib